At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELVN Enliven Treateutics
Trading 01-15 09:31:05 EST
26.11
+0.06
+0.23%
High26.19Low26.11Vol6.25K
Open26.19D1 Closing26.05Amplitude0.31%
Mkt Cap1.55BTradable Cap913.84MTotal Shares59.35M
T/O163.71KT/O Rate0.02%Tradable Shares35.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares
Reuters  ·  01-14 06:54
Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares
Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares
Reuters  ·  01-13 06:13
Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares
Enliven Therapeutics Director Richard A. Heyman Reports Sale of Common Shares
Reuters  ·  01-13 06:11
Enliven Therapeutics Director Richard A. Heyman Reports Sale of Common Shares
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data
Simply Wall St.  ·  01-11
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data
Enliven Therapeutics Files Initial Beneficial Ownership Statement for Director Garland J. Scott
Reuters  ·  01-10
Enliven Therapeutics Files Initial Beneficial Ownership Statement for Director Garland J. Scott
Analysts Are Bullish on Top Healthcare Stocks: Rubicon Organics (ROMJF), Enliven Therapeutics (ELVN)
TIPRANKS  ·  01-08
Analysts Are Bullish on Top Healthcare Stocks: Rubicon Organics (ROMJF), Enliven Therapeutics (ELVN)
Enliven Therapeutics Up Over 58%, on Pace for Largest Percent Increase Since September 2022 -- Data Talk
Dow Jones  ·  01-08
Enliven Therapeutics Up Over 58%, on Pace for Largest Percent Increase Since September 2022 -- Data Talk
Enliven Therapeutics Shares Surge on Positive Initial Data for Leukemia Treatment
Dow Jones  ·  01-08
Enliven Therapeutics Shares Surge on Positive Initial Data for Leukemia Treatment
Enliven Therapeutics Reports Positive Phase 1b Results for ELVN-001 in CML
Reuters  ·  01-08
Enliven Therapeutics Reports Positive Phase 1b Results for ELVN-001 in CML
BRIEF-Enliven Therapeutics Continues To Prepare For Phase 3 Trial Initiation In 2026
Reuters  ·  01-07
BRIEF-Enliven Therapeutics Continues To Prepare For Phase 3 Trial Initiation In 2026
Enliven Therapeutics Inc - Continues to Prepare for Phase 3 Trial Initiation in 2026 and the Commercialization of Elvn-001
THOMSON REUTERS  ·  01-07
Enliven Therapeutics Inc - Continues to Prepare for Phase 3 Trial Initiation in 2026 and the Commercialization of Elvn-001
Enliven Therapeutics Appoints Scott Garland to Board as Andrew Phillips Steps Down
Reuters  ·  01-07
Enliven Therapeutics Appoints Scott Garland to Board as Andrew Phillips Steps Down
Press Release: Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Dow Jones  ·  01-07
Press Release: Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares
Reuters  ·  2025-12-24
Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares
Enliven Therapeutics (ELVN): Taking Stock of Valuation After Leadership Shift and Upcoming ELVN-001 Trial
Simply Wall St.  ·  2025-12-15
Enliven Therapeutics (ELVN): Taking Stock of Valuation After Leadership Shift and Upcoming ELVN-001 Trial
Enliven Therapeutics Files Initial Beneficial Ownership Statement for President and CEO Richard A. Fair
Reuters  ·  2025-12-13
Enliven Therapeutics Files Initial Beneficial Ownership Statement for President and CEO Richard A. Fair
Enliven Therapeutics Grants CEO Richard Fair Stock Option Inducement Package
Reuters  ·  2025-12-12
Enliven Therapeutics Grants CEO Richard Fair Stock Option Inducement Package
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
THOMSON REUTERS  ·  2025-12-12
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
BRIEF-Enliven Therapeutics Announces New CEO To Drive Next Phase Of Development
Reuters  ·  2025-12-11
BRIEF-Enliven Therapeutics Announces New CEO To Drive Next Phase Of Development
Enliven Therapeutics Names Rick Fair CEO
Reuters  ·  2025-12-11
Enliven Therapeutics Names Rick Fair CEO

Introduction

Company Name.
Enliven Treateutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Issue price:
--